November 2025, New York, NY — Outlive.bio, the company pioneering Real-Time Longevity (RTL), has officially opened applications for its closed beta. Early participants will gain exclusive access to a system that integrates wearable data, at-home smart BMI scales, and optional blood pressure monitors (BPM) with on-demand lab work, annual biomarker testing, and personalized medical support.

The closed beta invites a select group of participants to help shape the future of personalized, data-driven healthcare. Members will receive full access at a founder rate of $499, which includes over $700 worth of lab testing, direct consultations with a cardiology advisor, and early access to Outlive’s RTL health platform that connects biometric tracking with real medical interventions.

Applications are evaluated based on each participant’s commitment to improving their health and engagement with modern wellness tools. Priority will be given to individuals who already use or plan to use smart scales, peptides, hormone replacement therapies (HRT or TRT), GLP-1 medications, and other longevity interventions.

“When I ran my first hormone panel in 2022, I got a $300 PDF and no real insight,” said Hayim Pinson, founder of Outlive. “We built Outlive to close that gap by connecting how you sleep, train, and recover with what’s happening in your blood. This is the foundation of Real-Time Longevity.”

“Our goal is to make precision medicine accessible and actionable,” said Dr. Menachem Jacobs, Outlive’s medical advisor and a cardiology resident at Yale. “By combining wearable data, smart home metrics, and lab biomarkers, we can personalize hormone, metabolic, and sleep optimization every day, not just once a year.”

Outlive brings together wearable data (Oura, Withings, Apple Health, Fitbit, Dexcom, and others) with smart BMI and BPM metrics to deliver physician-guided programs across hormone optimization, metabolic weight loss, sleep, and recovery. Members gain access to licensed clinicians, prescriptions, and targeted therapies including HRT, TRT, GLP-1 medications, and peptide-based interventions for a complete approach to health longevity.

Applications for the closed beta are now open and will be reviewed on a rolling basis.